Suppr超能文献

重症 COVID-19 患者中 I 型和 II 型干扰素产生的功能耗竭

Functional Exhaustion of Type I and II Interferons Production in Severe COVID-19 Patients.

作者信息

Ruetsch Caroline, Brglez Vesna, Crémoni Marion, Zorzi Kévin, Fernandez Céline, Boyer-Suavet Sonia, Benzaken Sylvia, Demonchy Elisa, Risso Karine, Courjon Johan, Cua Eric, Ichai Carole, Dellamonica Jean, Passeron Thierry, Seitz-Polski Barbara

机构信息

Laboratoire d'Immunologie, Centre Hospitalier Universitaire (CHU) de Nice, Université Côte d'Azur, Nice, France.

Centre Méditerranéen de Médecine Moléculaire (C3M), INSERM U1065, Université Côte d'Azur, Nice, France.

出版信息

Front Med (Lausanne). 2021 Jan 27;7:603961. doi: 10.3389/fmed.2020.603961. eCollection 2020.

Abstract

Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has emerged in Wuhan in December 2019 and has since spread across the world. Even though the majority of patients remain completely asymptomatic, some develop severe systemic complications. In this prospective study we compared the immunological profile of 101 COVID-19 patients with either mild, moderate or severe form of the disease according to the WHO classification, as well as of 50 healthy subjects, in order to identify functional immune factors independently associated with severe forms of COVID-19. Plasma cytokine levels, and cytokine levels upon non-specific stimulation of innate and adaptive immune cells, were measured at several time points during the course of the disease. As described previously, inflammatory cytokines IL1β, IL6, IL8, and TNFα associated with cytokine storm were significantly increased in the plasma of moderate and severe COVID-19 patients ( < 0.0001 for all cytokines). During follow-up, plasma IL6 levels decreased between the moment of admission to the hospital and at the last observation carried forward for patients with favorable outcome ( = 0.02148). After stimulation of immune cells from COVID-19 patients, reduced levels of both type I and type II interferons (IFNs) upon stimulation were correlated with increased disease severity [type I IFN (IFNα): > 0.0001 mild vs. moderate and severe; type II IFN (IFNγ): = 0.0002 mild vs. moderate and < 0.0001 mild vs. severe] suggesting a functional exhaustion of IFNs production. Stimulated IFNα levels lower than 2.1 pg/ml and IFNγ levels lower than 15 IU/mL at admission to the hospital were associated with more complications during hospitalization ( = 0.0098 and =0.0002, respectively). A low IFNγ level was also confirmed by multivariable analysis [ = 0.0349 OR = 0.98 (0.962; 0.999)] as an independent factor of complications. treatment with type IFNα restored type IFNγ secretion in COVID-19 patients while the secretion of pro-inflammatory cytokines IL6 and IL1β remained stable or decreased, respectively. These results (a) demonstrate a functional exhaustion of both innate and adaptive immune response in severe forms of COVID-19; (b) identify IFNα and IFNγ as new potential biomarkers of severity; and (c) highlight the importance of targeting IFNs when considering COVID-19 treatment in order to re-establish a normal balance between inflammatory and Th1 effector cytokines.

摘要

2019年12月,武汉出现了由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引起的2019冠状病毒病(COVID-19),此后已蔓延至全球。尽管大多数患者完全无症状,但仍有一些患者出现严重的全身并发症。在这项前瞻性研究中,我们根据世界卫生组织的分类,比较了101例轻度、中度或重度COVID-19患者以及50名健康受试者的免疫特征,以确定与COVID-19严重形式独立相关的功能性免疫因子。在疾病过程中的几个时间点测量了血浆细胞因子水平,以及先天和适应性免疫细胞非特异性刺激后的细胞因子水平。如先前所述,与细胞因子风暴相关的炎性细胞因子IL1β、IL6、IL8和TNFα在中度和重度COVID-19患者的血浆中显著升高(所有细胞因子均<0.0001)。在随访期间,预后良好的患者从入院到最后一次随访时血浆IL6水平下降(=0.02148)。刺激COVID-19患者的免疫细胞后,刺激后I型和II型干扰素(IFN)水平降低与疾病严重程度增加相关[I型IFN(IFNα):轻度与中度和重度相比,>0.0001;II型IFN(IFNγ):轻度与中度相比,=0.0002,轻度与重度相比,<0.0001],提示IFN产生功能耗竭。入院时刺激的IFNα水平低于2.1 pg/ml和IFNγ水平低于15 IU/mL与住院期间更多并发症相关(分别为=0.0098和=0.0002)。多变量分析也证实低IFNγ水平[=0.0349,OR=0.98(0.962;0.999)]是并发症的独立因素。用I型IFNα治疗可恢复COVID-19患者II型IFNγ的分泌,而促炎细胞因子IL6和IL1β的分泌分别保持稳定或下降。这些结果(a)表明严重形式的COVID-19中先天和适应性免疫反应均存在功能耗竭;(b)将IFNα和IFNγ确定为严重程度的新潜在生物标志物;(c)强调在考虑COVID-19治疗时靶向IFN的重要性,以便重新建立炎症和Th1效应细胞因子之间的正常平衡。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8413/7873370/f9c1ed86dfab/fmed-07-603961-g0001.jpg

相似文献

1
Functional Exhaustion of Type I and II Interferons Production in Severe COVID-19 Patients.
Front Med (Lausanne). 2021 Jan 27;7:603961. doi: 10.3389/fmed.2020.603961. eCollection 2020.
4
Dysregulated Interferon Response and Immune Hyperactivation in Severe COVID-19: Targeting STATs as a Novel Therapeutic Strategy.
Front Immunol. 2022 May 17;13:888897. doi: 10.3389/fimmu.2022.888897. eCollection 2022.
6
Dysregulated early transcriptional signatures linked to mast cell and interferon responses are implicated in COVID-19 severity.
Front Immunol. 2023 May 16;14:1166574. doi: 10.3389/fimmu.2023.1166574. eCollection 2023.
8
Th-1, Th-2, Th-9, Th-17, Th-22 type cytokine concentrations of critical COVID-19 patients after treatment with Remdesivir.
Immunobiology. 2023 May;228(3):152378. doi: 10.1016/j.imbio.2023.152378. Epub 2023 Mar 24.
10
Safety, Tolerability, and Immunogenicity of Interferons.
Pharmaceuticals (Basel). 2010 Apr 20;3(4):1162-1186. doi: 10.3390/ph3041162.

引用本文的文献

2
Bronchoalveolar lavage single-cell transcriptomics reveals immune dysregulations driving COVID-19 severity.
PLoS One. 2025 Feb 10;20(2):e0309880. doi: 10.1371/journal.pone.0309880. eCollection 2025.
4
Pulmonary surfactant and COVID-19: A new synthesis.
QRB Discov. 2022 Apr 22;3:e6. doi: 10.1017/qrd.2022.1. eCollection 2022.
5
Case Report: Intercurrent infections in COVID-19-induced sustained immunodepression: is interferon gamma a suitable drug?
Front Immunol. 2023 Jun 8;14:1183665. doi: 10.3389/fimmu.2023.1183665. eCollection 2023.
6
Immune response to BNT162b2 SARS-CoV-2 vaccine in patients living with HIV: The COVIH-DAPT study.
Front Immunol. 2023 Mar 6;14:1136723. doi: 10.3389/fimmu.2023.1136723. eCollection 2023.
8
Immune profiles to distinguish hospitalized versus ambulatory COVID-19 cases in older patients.
iScience. 2022 Dec 22;25(12):105608. doi: 10.1016/j.isci.2022.105608. Epub 2022 Nov 16.
9
Untargeted plasma metabolomic fingerprinting highlights several biomarkers for the diagnosis and prognosis of coronavirus disease 19.
Front Med (Lausanne). 2022 Sep 29;9:995069. doi: 10.3389/fmed.2022.995069. eCollection 2022.
10
Low baseline IFN-γ response could predict hospitalization in COVID-19 patients.
Front Immunol. 2022 Sep 26;13:953502. doi: 10.3389/fimmu.2022.953502. eCollection 2022.

本文引用的文献

1
Reduction of lymphocyte count at early stage elevates severity and death risk of COVID-19 patients: a hospital-based case-cohort study.
Arch Med Sci. 2020 Sep 15;19(5):1303-1313. doi: 10.5114/aoms.2020.99006. eCollection 2023.
2
Interferon deficiency can lead to severe COVID.
Nature. 2020 Nov;587(7834):374-376. doi: 10.1038/d41586-020-03070-1.
3
Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19.
N Engl J Med. 2020 Nov 19;383(21):2030-2040. doi: 10.1056/NEJMoa2022926. Epub 2020 Oct 8.
4
Early prediction of mortality risk among patients with severe COVID-19, using machine learning.
Int J Epidemiol. 2021 Jan 23;49(6):1918-1929. doi: 10.1093/ije/dyaa171.
5
Evasion of Type I Interferon by SARS-CoV-2.
Cell Rep. 2020 Oct 6;33(1):108234. doi: 10.1016/j.celrep.2020.108234. Epub 2020 Sep 19.
6
Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study.
Lancet Microbe. 2020 Oct;1(6):e245-e253. doi: 10.1016/S2666-5247(20)30115-4. Epub 2020 Aug 20.
7
The type I interferon response in COVID-19: implications for treatment.
Nat Rev Immunol. 2020 Oct;20(10):585-586. doi: 10.1038/s41577-020-00429-3.
8
Activation and evasion of type I interferon responses by SARS-CoV-2.
Nat Commun. 2020 Jul 30;11(1):3810. doi: 10.1038/s41467-020-17665-9.
9
Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis.
Nature. 2020 Dec;588(7836):146-150. doi: 10.1038/s41586-020-2600-6. Epub 2020 Jul 29.
10
Longitudinal analyses reveal immunological misfiring in severe COVID-19.
Nature. 2020 Aug;584(7821):463-469. doi: 10.1038/s41586-020-2588-y. Epub 2020 Jul 27.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验